You are here: Industry Insights > Bayer

News List

Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195) worldpharmanews
February 18, 2019
Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology...
Bayer to Obtain Rights to Vitrakvi and BAY 2731954 americanpharmaceuticalreview
February 18, 2019
Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and commercialization...
Moberg Pharma and Bayer Sign Exclusive License Agreement for MOB-015 in Europe pharmafocusasia
February 14, 2019
Moberg Pharma has entered into a license agreement granting the Consumer Health division of Bayer exclusive European rights to MOB-015.....
Post-Monsanto Era of Bayer Group: To Lay off 10,000+ Employees, Scale Back Business, and Develop Life Science PharmaSources/Youyi
January 08, 2019
Bayer formally acquired the U.S. agricultural company: Monsanto for a price of USD63 billion on June 7, 2018 upon approval of the relevant U.S. and European regulators.
FDA grants breakthrough device designation to Bayer, Merck’s AI for spotting CTEPH fiercebiotech
January 02, 2019
The FDA granted Bayer and Merck & Co. a breakthrough device designation for an artificial intelligence-based pattern recognition software used to spot a rare form of pulmonary hypertension in CT scans......
Imperial and Bayer to use AI for heart conditions pharmatimes
December 24, 2018
Researchers at Imperial and Bayer Pharmaceuticals are partnering up to explore how artificial intelligence (AI) can be used to accelerate the discovery of new drugs for heart conditions.
Bayer partners with Imperial College London for AI drug discovery pharmaceutical-technology
December 21, 2018
Germany-based Bayer Pharmaceuticals has partnered with Imperial College London to leverage artificial intelligence (AI) to drive drug discovery for heart disorders....
Bayer plans filings for prostate cancer drug darolutamide pharmaphorum
December 20, 2018
Bayer is planning regulatory filings of darolutamide in prostate cancer following phase III trial results showing it helped prevent the disease from spreading, in a niche where Pfizer and Johnson & Johnson have already gained a foothold.
FDA breakthrough designation for Bayer and Merck & Co’s AI software pharmaphorum
December 06, 2018
Bayer and Merck & Co have won a breakthrough device designation from the US regulator FDA for artificial intelligence software they are jointly developing.
FDA grants breakthrough device designation to artificial intelligence software for CTEPH pattern recognition from Bayer and MSD worldpharmanews
December 06, 2018
Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Pattern Recognition...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page